^
Association details:
| Biomarker: | MTAP deletion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
Published date:
04/04/2022
Excerpt:
...we report our single arm phase II trial (NCT02693717) that assesses pemetrexed in MTAPdef urothelial carcinoma (UC) with the primary endpoint of overall response rate (ORR). Three of 7 enrolled MTAPdef patients show response to pemetrexed (ORR 43%). Furthermore, a historic cohort shows 4 of 4 MTAPdef patients respond to pemetrexed as compared to 1 of 10 MTAP-proficient patients.
DOI:
10.1038/s41467-022-29397-z
Trial ID:
